Friday, August 12, 2022
    HomeHealthFirst injectable for HIV prevention isn't cost-effective

    First injectable for HIV prevention isn’t cost-effective


    A long-acting injectable to stop HIV an infection could also be producing hope {that a} new period within the battle in opposition to AIDS is about to start. However a newly printed evaluation advised the drugs won’t be cost-effective except the worth is significantly decrease, since less expensive drugs to stop HIV can be found.

    At problem is Apretude, which was approved late final yr by U.S. regulators as the primary various to a capsule — generally known as pre-exposure prophylaxis, or PrEP— that have to be taken day by day to stop HIV. The model and generic variations of the capsule are 99% effective, however solely when taken as prescribed. That has confirmed problematic as a result of not everybody adheres to the routine, and studies have discovered discontinuation charges are excessive and persist over time.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!


    Source link

    Related articles

    Stay Connected


    Latest posts